drugset / Trial / NCT06435923

A Trial to Assess the Absorption, Metabolism, Excretion, and Mass Balance of [14C]-Darigabat After a Single Oral Dose in Healthy Male Participants

NCT06435923

Phase 1 Completed 8 enrolled Cerevel Therapeutics, LLC
NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of this trial is to determine the mass balance, routes, and rates of elimination of total radioactivity and characterize the pharmacokinetics (PK) of darigabat, and total radioactivity in plasma and whole blood following administration of a single oral dose of \[14C\]-darigabat in healthy adult male participants.

Timeline

Start
2024-05-29
Primary completion
2024-07-02
Completion
2024-07-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Darigabat Small molecule Oral

Indications

No indication recorded.